Latest News

(UroToday.com) Tumor-only sequencing panels can capture many relevant pathogenic somatic mutations in patient tumors but also detect germline variants that are not represented in population-level germline variant databases and likely over-estimate tumor mutational burden (TMB)1. As many ethnic groups are under-represented in these population-level germline databases, the authors of this presentation hypothesized that TMB estimates in […]

(UroToday.com) The CARD trial was a randomized open-label study of cabazitaxel versus the alternative anti-androgen therapy in patients with metastatic castration resistant prostate cancer (mCRPC) who had progressed on docetaxel and also progressed on either enzalutamide or abiraterone within 12 months of therapy initiation. This study showed a statistically significant improvement in radiographic progression free survival […]

(UroToday.com) While alterations in the homologous recombination repair (HRR) genes BRCA1 and BRCA2 are associated with response to PARP inhibitors and certain chemotherapies, the relevance of alterations in other HRR genes for treatment response is less well understood. In this presentation, Dr. Westphalen presented analysis of alterations in homologous recombination repair denes across a pan-cancer cohort […]

(UroToday.com) Dr. Noel Clarke first discussed presentation 617, the MANSMED trial. He reviewed the trial schemia, which randomized 124 high-risk prostate cancer patients 1:1 to either standard of care or standard of care plus metformin.

(UroToday.com) Germline mutations in BRCA2 (gBRCA2) are associated with prostate cancers that are more aggressive and have poorer clinical outcomes relative to other prostate cancers. These tumors are associated with more genomic copy number alterations including loss of BRCA2, RB1, and amplification of MYC.

(UroToday.com) COSMIC-021 is a clinical trial platform testing the combination of the MET/VEGF/TAM kinase inhibitor cabozantinib in combination with the anti-PD-L1 drug atezolizumab. The rationale for this combination is based on data suggesting that cabozantinib promotes an immune-permissive environment that may enhance responses to immune checkpoint blockade, and clinical data showing promising combination activity in […]

(UroToday.com) Dr. Laurence Albiges provided a discussion of two clinical studies, one from the COSMIC-021 trial examining combination cabozantinib and atezolizumab in untreated metastatic clear cell renal cell carcinoma, and the other an RNA expression biomarker-driven trial of tyrosine kinase inhibitor versus nivolumab monotherapy versus nivolumab and ipilimumab.

(UroToday.com) The results from STAMPEDE Arm G comparing standard of care (SOC) to SOC plus the addition of abiraterone acetate in men with hormone-sensitive locally advanced or metastatic prostate cancer were initially presented and published in 2017. This data showed an overall survival benefit for the SOC + abiraterone arm. Subsequent analyses of this cohort have […]

(UroToday.com) In this presentation, Dr. Maria DeSantis reviewed the history of STAMPEDE for context on the data presented in abstract 611O for long term follow-up on outcomes in men with metastatic hormone-sensitive prostate cancer randomized to either standard of care or standard of care plus abiraterone acetate. She first focused on the results of the long-term […]

(UroToday.com)  Sunitinib was standard first line treatment for metastatic clear cell renal cell carcinoma (mccRCC) for many years until multiple clinical trials showed superior efficacy of various treatment combinations including nivolumab and ipilimumab in International Metastatic RCC Database Consortium (IMDC) intermediate or poor-risk disease. Combination nivolumab and ipilimumab resulted in a 42% objective response rate […]